John S Bradley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4232289/publications.pdf

Version: 2024-02-01

186209 155592 67 3,228 28 55 citations h-index g-index papers 67 67 67 3899 docs citations times ranked citing authors all docs

#	ARTICLE Therepolitic montraring of vancomycle for carlous mathicilia registrant (1) Stanbylococcus	IF	CITATIONS
1	aureus (i) infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of	0.5	640
2	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clinical Infectious Diseases, 2019, 68, e1-e47.	2.9	449
3	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clinical Infectious Diseases, 2019, 68, 895-902.	2.9	251
4	Osteoarticular Infections in Children. Infectious Disease Clinics of North America, 2015, 29, 557-574.	1.9	126
5	Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events. Pediatrics, 2009, 123, e609-e613.	1.0	120
6	Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children. Clinical Infectious Diseases, 2015, 61, 767-775.	2.9	115
7	Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 801-844.	0.6	96
8	Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era. Clinical Infectious Diseases, 2017, 64, 1699-1704.	2.9	85
9	Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children. Journal of the Pediatric Infectious Diseases Society, 2015, 4, e109-e116.	0.6	82
10	Meropenem Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation in the Neonate. Pediatric Infectious Disease Journal, 2008, 27, 794-799.	1.1	79
11	Emergence of Multidrug-Resistant Pneumococcal Serotype 35B among Children in the United States. Journal of Clinical Microbiology, 2017, 55, 724-734.	1.8	74
12	Comparative Study of Levofloxacin in the Treatment of Children With Community-Acquired Pneumonia. Pediatric Infectious Disease Journal, 2007, 26, 868-878.	1.1	73
13	Characteristics of Severe Bordetella pertussis Infection Among Infants <=90 Days of Age Admitted to Pediatric Intensive Care Units - Southern California, September 2009-June 2011. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 1-6.	0.6	62
14	Parents' perceived obstacles to pediatric clinical trial participation: Findings from the clinical trials transformation initiative. Contemporary Clinical Trials Communications, 2018, 9, 33-39.	0.5	62
15	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillina∈Resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review of the American Society of Healthâ∈System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy,	1.2	56
16	2020, 40, 363-367. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. Pediatric Infectious Disease Journal, 2016, 35, 752-759.	1.1	54
17	Community-acquired pneumonia in children: cell-free plasma sequencing for diagnosis and management. Diagnostic Microbiology and Infectious Disease, 2019, 94, 188-191.	0.8	51
18	A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection. Pediatric Infectious Disease Journal, 2016, 35, e239-e247.	1.1	47

#	Article	IF	Citations
19	Multicenter Surveillance of Streptococcus pneumoniae Isolates From Middle Ear and Mastoid Cultures in the 13-Valent Pneumococcal Conjugate Vaccine Era. Clinical Infectious Diseases, 2015, 60, 1339-45.	2.9	45
20	Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12–17 Years of Age. Pediatric Infectious Disease Journal, 2015, 34, 748-752.	1.1	41
21	Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms. Antimicrobial Agents and Chemotherapy, 2016, 60, 2150-2156.	1.4	37
22	Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. Journal of Clinical Pharmacology, 2018, 58, S108-S122.	1.0	37
23	Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia. Pediatric Infectious Disease Journal, 2018, 37, 893-900.	1.1	37
24	Invasive Pneumococcal Disease in Children's Hospitals: 2014–2017. Pediatrics, 2019, 144, .	1.0	32
25	Single-dose Pharmacokinetics of Daptomycin in Pediatric Patients 3–24 Months of Age. Pediatric Infectious Disease Journal, 2014, 33, 936-939.	1.1	30
26	Considerations Unique to Pediatrics for Clinical Trial Design in Hospitalâ€Acquired Pneumonia and Ventilatorâ€Associated Pneumonia. Clinical Infectious Diseases, 2010, 51, S136-S143.	2.9	29
27	Intravenous Zanamivir in Hospitalized Patients With Influenza. Pediatrics, 2017, 140, .	1.0	29
28	Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection. Pediatric Infectious Disease Journal, 2018, 37, 1130-1136.	1.1	29
29	Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Communityâ€Acquired Bacterial Pneumonia. Journal of Clinical Pharmacology, 2017, 57, 345-355.	1.0	27
30	Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing. Pharmacotherapy, 2017, 37, 361-378.	1.2	26
31	Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents. Pediatric Infectious Disease Journal, 2016, 35, 628-633.	1.1	25
32	Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study. Clinical Therapeutics, 2015, 37, 1340-1351.	1.1	24
33	Invasive pneumococcal infections in children following transplantation in the pneumococcal conjugate vaccine era. Transplant Infectious Disease, 2017, 19, e12630.	0.7	24
34	Unique Considerations in the Evaluation of Antibacterials in Clinical Trials for Pediatric Communityâ€Acquired Pneumonia. Clinical Infectious Diseases, 2008, 47, S241-S248.	2.9	22
35	Which antibiotic for resistant Gram-positives, and why?. Journal of Infection, 2014, 68, S63-S75.	1.7	22
36	Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure. Pediatric Infectious Disease Journal, 2016, 35, 813-815.	1.1	16

#	Article	IF	CITATIONS
37	Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis. Pediatric Infectious Disease Journal, 2020, 39, 814-823.	1.1	16
38	Pharmacokinetics of singleâ€dose ceftaroline fosamil in children with cystic fibrosis. Pediatric Pulmonology, 2017, 52, 1424-1434.	1.0	15
39	Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. Lancet Infectious Diseases, The, 2016, 16, e178-e189.	4.6	14
40	Perceived barriers to pediatrician and family practitioner participation in pediatric clinical trials: Findings from the Clinical Trials Transformation Initiative. Contemporary Clinical Trials Communications, 2018, 9, 7-12.	0.5	14
41	Antiviral treatment of childhood influenza: an update. Current Opinion in Pediatrics, 2018, 30, 438-447.	1.0	13
42	Extensive orf infection in a toddler with associated id reaction. Pediatric Dermatology, 2017, 34, e337-e340.	0.5	9
43	Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age. Antimicrobial Agents and Chemotherapy, 2015, 59, 4742-4749.	1.4	8
44	Multimodal Treatment of Rhinocerebral Mucormycosis in a Pediatric Patient With Relapsed Pre-B Acute Lymphoblastic Leukemia. Pediatric Infectious Disease Journal, 2018, 37, 555-558.	1.1	8
45	Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population. American Journal of Perinatology, 2020, 38, 804-809.	0.6	8
46	Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections. Pediatric Infectious Disease Journal, 2021, 40, 238-244.	1.1	8
47	Invasive Pneumococcal Disease in Infants Aged O–60 Days in the United States in the 13-Valent Pneumococcal Conjugate Vaccine Era. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 249-252.	0.6	6
48	Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47, 199-218.	0.8	6
49	Detection of <i>Neisseria gonorrhoeae</i> from Joint Aspirate by Metagenomic Sequencing in Disseminated Gonococcal Infection. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 367-369.	0.6	6
50	Spectrum of Viral Pathogens Identified in Children with Clinical Myocarditis (Pre-Coronavirus) Tj ETQq0 0 0 rgBT /018-24.	Overlock 1 0.9	.0 Tf 50 227 6
51	Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	5
52	Antimicrobial prescribing for treatment of serious infections caused by Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in pediatrics: an expert review. Expert Review of Anti-Infective Therapy, 2021, 19, 1107-1116.	2.0	5
53	Old and new antibiotics for pediatric pneumonia. Seminars in Respiratory Infections, 2002, 17, 57-64.	1.3	5
54	Prevalence of Hepatitis C Virus Antibody in Newborn Infants in Southern California in 2003. Pediatric Infectious Disease Journal, 2011, 30, 618-620.	1.1	4

#	Article	IF	CITATIONS
55	Advancing Pediatric Antibacterial Drug Development: A Critical Need to Reinvent our Approach. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 60-62.	0.6	4
56	Key clinical research priorities for the pediatric community during the COVID-19 pandemic. Pediatric Research, 2021, 89, 730-732.	1.1	4
57	176. Selected Impact of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) at Eight Children's Hospitals in the United States. 2014–2019. Open Forum Infectious Diseases, 2020, 7, S216-S217.	0.4	3
58	Two cases of type-a Haemophilus influenzae meningitis within the same week in the same hospital are phylogenetically unrelated but recently exchanged capsule genes. Microbial Genomics, 2020, 6, .	1.0	3
59	Selective Valve Removal for Melody Valve Endocarditis: Practice Variations in a Multicenter Experience. Pediatric Cardiology, 2022, 43, 894-902.	0.6	2
60	77Continued Decline in Invasive Pneumococcal Infections in Children Among 8 Children's Hospitals in the United States 2011 to 2013. Open Forum Infectious Diseases, 2014, 1, S2-S2.	0.4	1
61	Safety, Tolerability and Pharmacokinetics (PK) of Intravenous Zanamivir (IVZ) Treatment in Hospitalized Pediatric and Adolescent Patients with Influenza: A Phase II Open-Label, Multicenter, Single- Arm Study. Open Forum Infectious Diseases, 2016, 3, .	0.4	1
62	78Pneumococcal Meningitis among 8 Children's Hospitals in the United States in the 13-valent Pneumococcal Conjugate Vaccine Era. Open Forum Infectious Diseases, 2014, 1, S2-S3.	0.4	0
63	958Streptococcus pneumoniae Serotype 3 Invasive Infections in Children. Open Forum Infectious Diseases, 2014, 1, S278-S279.	0.4	0
64	Augmented Renal Clearance Using Vancomycin Population-Based Pharmacokinetic Modeling With Bayesian Estimation in Critically-Ill Pediatric Patients. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
65	Pneumococcal Invasive Disease in Infants Younger Than 60 Days in the United States in the 13-Valent Pneumococcal Conjugate Vaccine Era. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
66	2707. Non 13-Valent Pneumococcal Conjugate Vaccine Serotypes Predominate as Causes of Pneumococcal Otitis Media in Children. Open Forum Infectious Diseases, 2019, 6, S952-S952.	0.4	0
67	471. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate (TZD) in Adolescents with Acute Bacterial Skin and Skin Structure Tissue Infections (ABSSSI). Open Forum Infectious Diseases, 2019, 6, S230-S231.	0.4	0